Verzenio generics — when can they launch?
Verzenio (abemaciclib) · Eli Lilly · 4 active US patents · 0 expired
Where Verzenio sits in the generic timeline
Mid-term cliff: earliest active US patent for Verzenio expires in 2031 (~5 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 4 patents
FDA U-codes carved out by Verzenio patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2135 | (no description) |
U-1981 | (no description) |
Sample patent estate
Showing 4 of 4 active US patents. View full estate on the Verzenio drug page →
-
Eli Lilly and Co's patent US 7855211 protects a compound of formula (I) or its pharmaceutically acceptable salt for treating cell proliferative diseases.USPTO title: Protein kinase inhibitors
-
Eli Lilly and Co's patent US 7855211 protects a compound of formula (I) or its pharmaceutically acceptable salt for treating cell proliferative diseases.USPTO title: Protein kinase inhibitors
-
Eli Lilly and Co's US patent 7855211 protects a compound of formula (I) or its pharmaceutically acceptable salt for treating cell proliferative diseases.USPTO title: Protein kinase inhibitors
-
Eli Lilly and Co's US patent 7855211 protects a compound of formula (I) or its pharmaceutically acceptable salt for treating cell proliferative diseases.USPTO title: Protein kinase inhibitors
Sources
- FDA Orange Book — patents listed against Verzenio (NDA filed 2017)
- Verzenio drug profile — full patent estate, indications, clinical trials, pricing
- Eli Lilly patent portfolio
- Patent cliff 2031 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Verzenio — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →